| Patient | Lorraine Hansberry |
|---|---|
| Date of birth | 1993-05-19 |
| Identifiers | MRN HR-ML034-SYN; SSN (made up) 000-34-7158 |
| Document date | 2026-04-20 |
| Author | Odette Marchetti-Fields, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two months of epigastric and back pain, weight loss, black stools and near-fainting in a woman of 32: examination, blood tests, and urgent upper endoscopy and pancreas-protocol CT [S]
This fictional modern episode addresses the presenting concerns below. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
5 later historical claims are omitted because they describe events after the index age. See the teaching note.
Historical biography with true dates. These events are not part of the synthetic care timeline.
No historical medical events are recorded.
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| father | Died suddenly of a cerebral hemorrhage when she was sixteen; no cancer recorded in the cited source | D (CLM-0003) |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfast | One tablet daily before breakfast | Oral route | 2026-04-20 | active | S |
Positive for the concerns in the history of present illness. Alert, articulate and exact; worried and tired; PHQ-2 negative; no thoughts of self-harm. No other systems reported as affected in this synthetic episode. [S]
Alert and engaged. Independent; working full days until the last two weeks, when tiredness and pain cut her writing to the mornings (ECOG performance status 1). [S]
Vital signs recorded on 2026-04-20; see the Vital Signs section. Mental status: Alert, articulate and exact; worried and tired; PHQ-2 negative; no thoughts of self-harm. The physical examination is limited to the findings relevant to this synthetic episode. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-20 | Body height | 163 | cm | S |
| 2026-04-20 | Body weight | 56.2 | kg | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 21.2 | kg/m2 | S |
| 2026-04-20 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-04-20 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-04-20 | Heart rate | 102 | /min | S |
| 2026-04-20 | Respiratory rate | 16 | /min | S |
| 2026-04-20 | Body temperature | 36.8 | Cel | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-20 | Hemoglobin [Mass/volume] in Blood | 9.1 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-04-20 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 74 | fL | 80-100 fL | Low | S |
| 2026-04-20 | Leukocytes [#/volume] in Blood by Automated count | 7.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-04-20 | Platelets [#/volume] in Blood by Automated count | 388 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-04-20 | Ferritin [Mass/volume] in Serum or Plasma | 6 | ng/mL | 15-150 ng/mL | Low | S |
| 2026-04-20 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-20 | Potassium [Moles/volume] in Serum or Plasma | 4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-20 | Creatinine [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-04-20 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 118 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-20 | Glucose [Mass/volume] in Serum or Plasma | 132 | mg/dL | 70-99 mg/dL | High | S |
| 2026-04-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 48 | U/L | 7-35 U/L | High | S |
| 2026-04-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 41 | U/L | 8-35 U/L | High | S |
| 2026-04-20 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 236 | U/L | 35-104 U/L | High | S |
| 2026-04-20 | Bilirubin.total [Mass/volume] in Serum or Plasma | 1.6 | mg/dL | 0.1-1.2 mg/dL | High | S |
| 2026-04-20 | Albumin [Mass/volume] in Serum or Plasma | 3.6 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-04-20 | Lipase [Enzymatic activity/volume] in Serum or Plasma | 52 | U/L | 13-60 U/L | Normal | S |
| 2026-04-20 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.6 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes | High | S |
| 2026-04-20 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-04-20 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 5 | {score} | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Epigastric pain for about two months, boring through to the back and worse after meals and lying flat, with nausea, early fullness, a loss of 5 kg (8 percent of her weight), and pale, loose stools: an upper abdominal cause such as a bleeding ulcer or a pancreatic or duodenal tumor must be found. Upper endoscopy and pancreas-protocol CT booked this week | active | confirmed | R10.13 | S — Synthetic presenting problem anchored to the documented collapse in pain and the account of a suspected duodenal ulcer. Superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic upper gastrointestinal blood loss: black stools on and off for three weeks, two near-fainting spells, hemoglobin 9.1 g/dL, MCV 74 fL, ferritin 6 ng/mL | active | confirmed | D50.0 | S — Synthetic finding anchored to the documented account that she was told she had anemia and bleeding ulcers. |
| New hyperglycemia: A1c 6.6% and random glucose 132 mg/dL in a lean woman of 32 who is losing weight; new diabetes with weight loss can be the first sign of a pancreatic cancer, so it is to be confirmed and explained, not labeled type 2 | active | confirmed | R73.09 | S — Synthetic finding; superseded when diabetes due to the pancreatic cancer was recorded at the second visit. |